基本信息
专利与奖励
专利成果
[1] 姜海, 陈奭爽, 褚衍凯. 基于细胞死活表型的药物靶点拮抗剂的新型筛选系统. 202110385275.1, 2021-04-09.[2] 姜海, 李晓曦, 张艳丽, 虞皎. 一种用于侵袭性淋巴瘤的早期诊断检测试剂盒. CN: CN110438222A, 2019-11-12.[3] 姜海, 李晓曦, 陈德桂, 郑丽婷. 一种侵袭性淋巴瘤小鼠模型的制备及应用. CN: CN110438158A, 2019-11-12.[4] 姜海, 李晓曦, 张艳丽, 赵洁. 一种用于淋巴瘤对化疗药物的疗效预测与评价的检测试剂盒. CN: CN110438221A, 2019-11-12.[5] 姜海, 张雷, 徐亮, 李培学. Shank2基因的功能与用途. CN: CN109248318B, 2021-02-12.
出版信息
发表论文
[1] 姜海. DCK confers sensitivity of DCTD-positive cancer cells to oxidized methylcytidines. Protein & Cell[J]. 2022, 第 1 作者 通讯作者 1-6, https://doi.org/10.1093/procel/pwac028.[2] Shan, Lin, Yu, Jiao, He, Zhengjin, Chen, Shishuang, Liu, Mingxian, Ding, Hongyu, Xu, Liang, Zhao, Jie, Yang, Ailing, Jiang, Hai. Defining relative mutational difficulty to understand cancer formation. CELL DISCOVERY[J]. 2020, 第 10 作者 通讯作者 6(1): https://doaj.org/article/708db0348cf0462cba3c2cfc9270ff59.[3] Liang Xu, Peixue Li, Xue Hao, Yi Lu, Mingxian Liu, Wenqian Song, Lin Shan, Jiao Yu, Hongyu Ding, Shishuang Chen, Ailing Yang, Yi Arial Zeng, Lei Zhang, Hai Jiang. SHANK2 is a frequently amplified oncogene with evolutionarily conserved roles in regulating Hippo signaling. PROTEIN & CELL[J]. 2020, 第 14 作者 通讯作者 12(3): 174-193, https://doaj.org/article/94fd8f6207094875a9562a463d56e753.[4] Ding, Hongyu, Zhao, Jie, Zhang, Yanli, Yu, Jiao, Liu, Mingxian, Li, Xiaoxi, Xu, Liang, Lin, Minghui, Liu, Chuan, He, Zhengjin, Chen, Shishuang, Jiang, Hai. Systematic Analysis of Drug Vulnerabilities Conferred by Tumor Suppressor Loss. CELL REPORTS[J]. 2019, 第 12 作者 通讯作者 27(11): 3331-+, https://doaj.org/article/1fe6f63894754e35a90c4786fcce99d3.[5] Li, Xiaoxi, Zhang, Yanli, Zheng, Liting, Liu, Mingxian, Chen, Charlie Degui, Jiang, Hai. UTX is an escape from X-inactivation tumor-suppressor in B cell lymphoma. NATURE COMMUNICATIONS[J]. 2018, 第 6 作者 通讯作者 9(1): http://202.127.25.143/handle/331003/3509.[6] Wang, N, Ding, H, Liu, C, Li, X, Wei, L, Yu, J, Liu, M, Ying, M, Gao, W, Jiang, H, Wang, Y. A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk. ONCOGENE[J]. 2015, 34(40): 5198-5205, https://www.webofscience.com/wos/woscc/full-record/WOS:000362233400009.[7] Liu, Chuan, Ding, Hongyu, Li, Xiaoxi, Pallasch, Christian P, Hong, Liya, Guo, Dianwu, Chen, Yi, Wang, Difei, Wang, Wei, Wang, Yajie, Hemann, Michael T, Jiang, Hai. A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency. EMBO MOLECULAR MEDICINE[J]. 2015, 第 12 作者7(4): 438-449, https://www.webofscience.com/wos/woscc/full-record/WOS:000352612400009.